{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T09:18:37Z","timestamp":1754558317244},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,16]]},"DOI":"10.7759\/cureus.41957","type":"journal-article","created":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T16:17:43Z","timestamp":1689524263000},"source":"Crossref","is-referenced-by-count":1,"title":["The Potential Role of Torsemide in Optimizing Loop Diuretic Therapy for Heart Failure Patients"],"prefix":"10.7759","author":[{"given":"V. K","family":"Chopra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. P","family":"Mohanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Kher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja Ram","family":"Mantri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Zalte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarnath","family":"Sugumaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthilnathan","family":"Mohanasundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Epidemiology and prevention in India","volume":"23","author":"Huffman M","year":"2010","unstructured":"Huffman M, Prabhakaran D. Epidemiology and prevention in India. Natl Med J India. 2010, 23:283-8.","journal-title":"Natl Med J India"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10389-019-01141-w","article-title":"Financial burden of heart failure in a developing country: cost analysis from Manipal Heart Failure Registry, India","volume":"29","author":"Singh A","year":"2021","unstructured":"Singh A, Chauhan S, Devasia T, et al.. Financial burden of heart failure in a developing country: cost analysis from Manipal Heart Failure Registry, India. J Public Health (Berl). 2021, 29:585-94. 10.1007\/s10389-019-01141-w","journal-title":"J Public Health (Berl)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2017.11.015","article-title":"Management protocols for chronic heart failure in India","volume":"70","author":"Mishra S","year":"2018","unstructured":"Mishra S, Mohan JC, Nair T, et al.. Management protocols for chronic heart failure in India. Indian Heart J. 2018, 70:105-27. 10.1016\/j.ihj.2017.11.015","journal-title":"Indian Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"28","author":"Writing Committee Members","year":"2022","unstructured":"Writing Committee Members. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. J Card Fail. 2022, 28:e1-e167. 10.1016\/j.cardfail.2022.02.010","journal-title":"J Card Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-017-0351-y","article-title":"Acute heart failure: definition, classification and epidemiology","volume":"14","author":"Kurmani S","year":"2017","unstructured":"Kurmani S, Squire I. Acute heart failure: definition, classification and epidemiology. Curr Heart Fail Rep. 2017, 14:385-92. 10.1007\/s11897-017-0351-y","journal-title":"Curr Heart Fail Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2015.10.386","article-title":"Decongestion: diuretics and other therapies for hospitalized heart failure","volume":"68 Suppl 1","author":"Vazir A","year":"2016","unstructured":"Vazir A, Cowie MR. Decongestion: diuretics and other therapies for hospitalized heart failure. Indian Heart J. 2016, 68 Suppl 1:S61-8. 10.1016\/j.ihj.2015.10.386","journal-title":"Indian Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.09.023","article-title":"Integrative assessment of congestion in heart failure throughout the patient journey","volume":"6","author":"Girerd N","year":"2018","unstructured":"Girerd N, Seronde MF, Coiro S, et al.. Integrative assessment of congestion in heart failure throughout the patient journey. JACC Heart Fail. 2018, 6:273-85. 10.1016\/j.jchf.2017.09.023","journal-title":"JACC Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens W","year":"2019","unstructured":"Mullens W, Damman K, Harjola VP, et al.. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019, 21:137-55. 10.1002\/ejhf.1369","journal-title":"Eur J Heart Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.12.052","article-title":"Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure","volume":"43","author":"L\u00f3pez B","year":"2004","unstructured":"L\u00f3pez B, Querejeta R, Gonz\u00e1lez A, S\u00e1nchez E, Larman M, D\u00edez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004, 43:2028-35. 10.1016\/j.jacc.2003.12.052","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.04.080","article-title":"Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure","volume":"50","author":"L\u00f3pez B","year":"2007","unstructured":"L\u00f3pez B, Gonz\u00e1lez A, Beaumont J, Querejeta R, Larman M, D\u00edez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007, 50:859-67. 10.1016\/j.jacc.2007.04.080","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199141010-00008","article-title":"Torasemide. A review of its pharmacological properties and therapeutic potential","volume":"41","author":"Friedel HA","year":"1991","unstructured":"Friedel HA, Buckley MM. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs. 1991, 41:81-103. 10.2165\/00003495-199141010-00008","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(20)31387-5","article-title":"Impact of torsemide on cardiac remodeling and renin-angiotensin-aldosterone system in heart failure patients","volume":"1","author":"Abraham B","year":"2020","unstructured":"Abraham B, Megaly M, Sous M, et al.. Impact of torsemide on cardiac remodeling and renin-angiotensin-aldosterone system in heart failure patients. J Am Coll Cardiol. 2020, 1:760. 10.1016\/S0735-1097(20)31387-5","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/BF00541465","article-title":"Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study","volume":"31 Suppl","author":"Scheen AJ","year":"1986","unstructured":"Scheen AJ, Vancrombreucq JC, Delarge J, Luyckx AS. Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol. 1986, 31 Suppl:35-42. 10.1007\/BF00541465","journal-title":"Eur J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s1388-9842(02)00122-8","article-title":"Torasemide in chronic heart failure: results of the TORIC study","volume":"4","author":"Cosin J","year":"2002","unstructured":"Cosin J, D\u00edez J, TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002, 4:507-13. 10.1016\/s1388-9842(02)00122-8","journal-title":"Eur J Heart Fail"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s1388-9842(03)00150-8","article-title":"Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life","volume":"5","author":"M\u00fcller K","year":"2003","unstructured":"M\u00fcller K. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life. Eur J Heart Fail. 2003, 5:793-801. 10.1016\/s1388-9842(03)00150-8","journal-title":"Eur J Heart Fail"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2019.0114","article-title":"Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: preliminary results from the randomized TORNADO trial","volume":"26","author":"Balsam P","year":"2019","unstructured":"Balsam P, Oziera\u0144ski K, Marchel M, et al.. Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: preliminary results from the randomized TORNADO trial. Cardiol J. 2019, 26:661-8. 10.5603\/CJ.a2019.0114","journal-title":"Cardiol J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-019-09771-8","article-title":"READY: relative efficacy of loop diuretics in patients with chronic systolic heart failure-a systematic review and network meta-analysis of randomised trials","volume":"24","author":"T\u00e4ger T","year":"2019","unstructured":"T\u00e4ger T, Fr\u00f6hlich H, Seiz M, Katus HA, Frankenstein L. READY: relative efficacy of loop diuretics in patients with chronic systolic heart failure-a systematic review and network meta-analysis of randomised trials. Heart Fail Rev. 2019, 24:461-72. 10.1007\/s10741-019-09771-8","journal-title":"Heart Fail Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.23924","article-title":"Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the transform-HF randomized clinical trial","volume":"329","author":"Mentz RJ","year":"2023","unstructured":"Mentz RJ, Anstrom KJ, Eisenstein EL, et al.. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the transform-HF randomized clinical trial. JAMA. 2023, 329:214-23. 10.1001\/jama.2022.23924","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e3181a71a78","article-title":"Loop diuretics in patients with heart failure: time to change to torsemide?","volume":"53","author":"Pitt B","year":"2009","unstructured":"Pitt B, Nicklas J. Loop diuretics in patients with heart failure: time to change to torsemide?. J Cardiovasc Pharmacol. 2009, 53:435-7. 10.1097\/FJC.0b013e3181a71a78","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e3181a717f7","article-title":"Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide","volume":"53","author":"Harada K","year":"2009","unstructured":"Harada K, Izawa H, Nishizawa T, et al.. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol. 2009, 53:468-73. 10.1097\/FJC.0b013e3181a717f7","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.10.059","article-title":"Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF trial)","volume":"117","author":"Mentz RJ","year":"2016","unstructured":"Mentz RJ, Hasselblad V, DeVore AD, et al.. Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF trial). Am J Cardiol. 2016, 117:404-11. 10.1016\/j.amjcard.2015.10.059","journal-title":"Am J Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(01)00903-2","article-title":"Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure","volume":"111","author":"Murray MD","year":"2001","unstructured":"Murray MD, Deer MM, Ferguson JA, et al.. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001, 111:513-20. 10.1016\/s0002-9343(01)00903-2","journal-title":"Am J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.108.821785","article-title":"Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?","volume":"2","author":"Felker GM","year":"2009","unstructured":"Felker GM, O'Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?. Circ Heart Fail. 2009, 2:56-62. 10.1161\/CIRCHEARTFAILURE.108.821785","journal-title":"Circ Heart Fail"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06032-x","article-title":"Clinical implication of initial intravenous diuretic dose for acute decompensated heart failure","volume":"12","author":"Yoshioka K","year":"2022","unstructured":"Yoshioka K, Maeda D, Okumura T, et al.. Clinical implication of initial intravenous diuretic dose for acute decompensated heart failure. Sci Rep. 2022, 12:2127. 10.1038\/s41598-022-06032-x","journal-title":"Sci Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(94)90489-8","article-title":"Dose-response study of intravenous torsemide in congestive heart failure","volume":"128","author":"Hariman RJ","year":"1994","unstructured":"Hariman RJ, Bremner S, Louie EK, et al.. Dose-response study of intravenous torsemide in congestive heart failure. Am Heart J. 1994, 128:352-7. 10.1016\/0002-8703(94)90489-8","journal-title":"Am Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/166350-the-potential-role-of-torsemide-in-optimizing-loop-diuretic-therapy-for-heart-failure-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:20Z","timestamp":1707509120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/166350-the-potential-role-of-torsemide-in-optimizing-loop-diuretic-therapy-for-heart-failure-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,16]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.41957","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,16]]}}}